Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19 blood clot mystery: new study aims to unravel why some patients develop dangerous clots

NCT ID NCT04356950

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at blood clotting in 175 hospitalized COVID-19 patients. Researchers used a special test to measure how quickly and strongly blood clots form, and whether a protein called thrombomodulin can slow this process. The goal was to understand why some COVID-19 patients develop dangerous blood clots, which could help guide future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors identify which COVID-19 patients are at highest risk for blood clots, leading to better prevention and treatment strategies.
What could go wrong
This is an observational study, not a treatment trial. It does not test any new drug or therapy, so it cannot directly improve patient outcomes. The findings may not apply to all COVID-19 patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLOOD COAGULATION DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease COVID-19 disseminated intravascular coagulation infectious disease with sepsis Sepsis thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLOOD COAGULATION DISORDERS COVID-19 DISSEMINATED INTRAVASCULAR COAGULATION SEPSIS THROMBIN

Contacts and locations

Locations

  • CHU de Bordeaux

    Bordeaux, France

  • CHU de Limoges

    Limoges, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nimes

    Nîmes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.